These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 414829)

  • 1. Comparison of radiotherapy with and without razoxane (ICRF 159) in the treatment of soft tissue sarcomas.
    Hellmann K; Ryall RD; Macdonald E; Newton KA; James SE; Jones S
    Cancer; 1978 Jan; 41(1):100-7. PubMed ID: 414829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of radiotherapy and razoxane (ICRF 159) for chondrosarcoma.
    Ryall RD; Bates T; Newton KA; Hellmann K
    Cancer; 1979 Sep; 44(3):891-5. PubMed ID: 113077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical experiences with radiotherapy and ICRF 159 in sarcomas].
    Rhomberg W; Mesche E; Gefeller D; Hassenstein E
    Strahlentherapie Sonderb; 1978; 75():110-4. PubMed ID: 400195
    [No Abstract]   [Full Text] [Related]  

  • 4. Radiotherapy and ICRF 159 in the treatment of soft tissue sarcomas.
    Ryall RD
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):133-4. PubMed ID: 632140
    [No Abstract]   [Full Text] [Related]  

  • 5. Radiotherapy combined with ICRF 159 (NSC 129943).
    Rhomberg WU
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):121-6. PubMed ID: 204615
    [No Abstract]   [Full Text] [Related]  

  • 6. Further experience with rezoxane (ICRF 159; -- NSC --129943) in treating Kaposi's sarcoma.
    Olweny CL; Sikyewunda W; Otim D
    Oncology; 1980; 37(3):174-6. PubMed ID: 7360489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of blast cell crisis of chronic myeloid leukemia with ICRF-159 (razoxane).
    Bakowski MT; Brearley RL; Wrigley PF
    Cancer Treat Rep; 1979; 63(11-12):2085-7. PubMed ID: 294308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy vs. radiotherapy and razoxane in the treatment of soft tissue sarcomas: final results of a randomized study.
    Rhomberg W; Hassenstein EO; Gefeller D
    Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1077-84. PubMed ID: 8985029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy.
    Liesmann J; Belt R; Haas C; Hoogstraten B
    Cancer; 1981 Apr; 47(8):1959-62. PubMed ID: 6784914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of ICRF-187 in squamous cell carcinoma of the head and neck.
    Wheeler RH; Bricker LJ; Natale RB; Baker SR
    Cancer Treat Rep; 1984 Feb; 68(2):427-8. PubMed ID: 6421483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICRF-159: current status and clinical prospects.
    Bellet RE; Rozencweig M; Von Hoff DD; Penta JS; Wasserman TH; Muggia FM
    Eur J Cancer (1965); 1977 Nov; 13(11):1293-8. PubMed ID: 590286
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical trial of razoxane and radiotherapy for inoperable carcinoma of the bronchus.
    Spittle MF; Bush H; James SE; Hellmann K
    Int J Radiat Oncol Biol Phys; 1979 Sep; 5(9):1649-51. PubMed ID: 231597
    [No Abstract]   [Full Text] [Related]  

  • 13. A trial of razoxane (ICRF-159) in patients with prior therapy for Hodgkin's lymphoma.
    Corder MP; McFadden DB; Bell SJ
    Cancer; 1984 Oct; 54(8):1496-8. PubMed ID: 6383594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant oral razoxane (ICRF-159) in resectable colorectal cancer.
    Gilbert JM; Hellmann K; Evans M; Cassell PG; Stoodley B; Ellis H; Wastell C
    Cancer Chemother Pharmacol; 1982; 8(3):293-9. PubMed ID: 7127660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas.
    Borden EC; Ash A; Enterline HT; Rosenbaum C; Laucius JF; Paul AR; Falkson G; Lerner H
    Am J Clin Oncol; 1982 Aug; 5(4):417-20. PubMed ID: 6956236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ICRF-159 (razoxane) in patients with advanced squamous cell carcinoma of the uterine cervix. For the Gynecologic Oncology Group.
    Conroy JF; Lewis GC; Blessing JA; Mangan C; Hatch K; Wilbanks G
    Am J Clin Oncol; 1984 Apr; 7(2):131-3. PubMed ID: 6702716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ICRF-159 (razoxane) in the treatment of pediatric solid tumors: a Southwest Oncology Group study.
    Dyment PG; Starling KA; Land VJ; Cangir A; Komp DM; Sexauer CL
    Cancer Treat Rep; 1979 Aug; 63(8):1397-8. PubMed ID: 476712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of razoxane in the management of recurrent adenocarcinoma of the ovary: a Gynecologic Oncology Group study.
    Conroy JF; Blessing JA; Kessinger A; Homesley HD
    Cancer Treat Rep; 1984 Feb; 68(2):439-40. PubMed ID: 6697335
    [No Abstract]   [Full Text] [Related]  

  • 19. A small prospective study of chordomas treated with radiotherapy and razoxane.
    Rhomberg W; Böhler FK; Novak H; Dertinger S; Breitfellner G
    Strahlenther Onkol; 2003 Apr; 179(4):249-53. PubMed ID: 12707714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled prospective trial of adjuvant razoxane in resectable colorectal cancer.
    Gilbert JM; Cassell PC; Ellis H; Wastell C; Hellmann K; Evans MG; Stoodley BJ
    Recent Results Cancer Res; 1981; 79():48-58. PubMed ID: 7029684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.